Orgaran (danaparoid) / Merck (MSD) - LARVOL DELTA

Bleeding, thrombosis, and anti-Xa monitoring in danaparoid-treated patients with suspected heparin-induced thrombocytopenia: a retrospective single-center study. (PubMed, Haematologica) - "Not available."

Journal • Retrospective data • Cardiovascular • Hematological Disorders • Thrombocytopenia • Thrombosis

Explosive Multiterritorial Arterial Thrombosis Following Brief Heparin Exposure: A Diagnostic Pitfall in the Cath Lab. (PubMed, Case Rep Cardiol) - "This followed a brief nadroparin exposure 8 days prior...Management involved non-heparin anticoagulation (danaparoid sodium) and thrombectomies...The immediate "anaphylactoid-like" reaction following a heparin bolus is often misidentified as contrast allergy, delaying life-saving intervention. Suspect HIT in acute systemic reactions or multifocal thrombosis after heparin exposure, regardless of initial platelet counts."

Journal • Allergy • Cardiovascular • Hematological Disorders • Immunology • Myocardial Infarction • Thrombocytopenia • Thrombosis

Room-Temperature Stability of Argatroban, Danaparoid, and Fondaparinux in Plasma: A Multicenter Study. (PubMed, Thromb Haemost) - "no need."

Clinical • Journal

Stability durations of argatroban, danaparoid sodium, and fondaparinux sodium assays in plasma samples stored at room temperature. (ISTH 2026) - "The limitations of this study may include the sample size, though it is sufficient (>30 samples/molecule) given the frequency of these prescriptions in our laboratories, as well as the use of frozen samples. However, since freezing may represent a more challenging condition than fresh plasma measurements, our results can be extrapolated to routine room-temperature storage conditions Table or Figure Upload (1) Page 2 DOI*10.1016/j.rpth.2026.105400"

Therapeutic anticoagulation in a murine model of vaccine-induced immune thrombocytopenia and thrombosis (VITT) (ISTH 2026) - "Parallel to immunization, therapy groups received either heparin (i.v. C) Survival rates of mice receiving recombinantly produced VITT antibody CR22046 (left panel, red) or CR23010 (right panel, black) without therapy or with heparin (dotted) or danaparoid (dashed) compared to negative control (green). Page 2 DOI*10.1016/j.rpth.2026.104389"

Preclinical • Cardiovascular • Hematological Disorders • Immune Thrombocytopenic Purpura • Infectious Disease • Thrombocytopenia • Thrombocytopenic Purpura • Thrombosis

Implementation of a structured diagnostic pathway and a multidisciplinary management for heparin-induced thrombocytopenia: experience from a high-volume CPB cardiac surgery and ECMO center (ISTH 2026) - "After switching (9 argatroban; 2 danaparoid; 3 DOACs), median time to >50% platelet recovery from nadir was 3 days [2.75; 4.25]; median time to thrombocytopenia resolution was 7 days [3; 16] (3.5 days excluding persistent cases). Page 2 Table or Figure Upload (2) Table 1. DOI*10.1016/j.rpth.2026.104413"

Surgery • Cardiovascular • Hematological Disorders • Thrombocytopenia

Clinical and biological description of heparin-induced thrombocytopenia in transplant recipients: a single-center retrospective study (ISTH 2026) - "Sixteen (64%) patients were initially treated with argatroban and 5 (20%) with danaparoid. Conclusions These results highlight the importance of functional tests to confirm the diagnosis of HIT in transplant recipients, particularly cardiac transplant recipients, and demonstrate the difficulty of managing these especially frail patients. DOI*10.1016/j.rpth.2026.104406"

Retrospective data • Cardiovascular • Hematological Disorders • Solid Organ Transplantation • Thrombocytopenia • Thrombosis • Transplantation

Delayed-type hypersensitivity to low-molecular-weight heparin and cross-reactivity to fondaparinux and danaparoid in a twin pregnancy. (PubMed, Obstet Med) - "A case of generalised urticaria reaction to enoxaparin, fondaparinux and danaparoid in a twin pregnancy complicated by deep vein thrombosis is presented. The management challenges in pregnant women intolerant of parenteral anticoagulants are discussed."

Journal • Cardiovascular • Dermatology • Hematological Disorders • Immunology • Thrombosis • Urticaria

Optimizing Anticoagulant Strategies in Pregnancy-Associated HIT and Acute Stroke in a Real-World Community Setting (THSNA 2026) - "Case Presentation: A 30-year-old gravid 1 para 0 woman with a history of unprovoked lower-extremity deep vein thrombosis (DVT), maintained on rivaroxaban for secondary prophylaxis, was transitioned to LMWH (enoxaparin) at 7 weeks' gestation...Enoxaparin was discontinued, and argatroban was initiated post-EVT, followed by transition to subcutaneous danaparoid and ultimately fondaparinux for ongoing anticoagulation through pregnancy...This case demonstrates that, when supported by coordinated multidisciplinary expertise, community hospitals can effectively deliver highly specialized, patient-centered thrombosis care. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author."

Clinical • Real-world • Real-world evidence • Cardiovascular • Hematological Disorders • Ischemic stroke • Thrombocytopenia • Thrombosis

When pregnancy, HIT, and stroke collide: Navigating complex thrombotic care in a community-based setting (ASH 2025) - "Case Presentation: A 30-year-old woman, gravida 1 para 0, with a history of unprovoked lower extremity deep vein thrombosis (DVT) on chronic rivaroxaban for secondary prophylaxis was transitioned to low-molecular-weight heparin (enoxaparin) upon confirmation of pregnancy at 7 weeks' gestation...Enoxaparin was discontinued, and argatroban was initiated post-EVT, later transitioning to subcutaneous danaparoid, and ultimately fondaparinux for the remainder of her pregnancy...Another important feature of this case is that it was successfully managed entirely within a regional community hospital system, allowing the patient to stay close to her family and access local rehabilitation services. This case report highlights the ability of community-based hospitals to provide high-acuity, patient-centered care through strong interdisciplinary collaboration."

Cardiovascular • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Thrombocytopenia • Thrombosis

Platelet dynamics and clinical outcomes in patients with heparin-induced thrombocytopenia – single center experience (ASH 2025) - "Several agents, such as bivalirudin, argatroban, danaparoid, and fondaparinux, have been used for the treatment of HIT. The dynamics of platelet counts after diagnosis may be an important tool for assessing treatment efficacy. Despite treatment, the mortality rate in critically ill patients with HIT remains high."

Clinical • Clinical data • Cardiovascular • Hematological Disorders • Thrombocytopenia

Heparin-induced thrombocytopenia after percutaneous coronary intervention complicated by hemothorax and pulmonary thromboembolism: The scylla and charybdis of hematology (ASH 2025) - "Those with a confirmed diagnosis need to be started on therapeutic-dose anticoagulation with argatroban, danaparoid, bivalirudin, or fondaparinux. Our case highlights a unique case of HIT with both thrombosis and life-threatening bleeding post-PCI that precluded the use of both anticoagulation and antiplatelets, underscoring the complexity of care, need for a multidisciplinary approach, and individualization of treatment in such cases."

Cardiovascular • Cerebral Hemorrhage • Chronic Kidney Disease • Diabetes • Endocrine Disorders • Hematological Disorders • Hypertension • Metabolic Disorders • Nephrology • Pulmonary Embolism • Renal Disease • Respiratory Diseases • Thrombocytopenia

Evaluating the Safety of Combining Tyrosine Kinase Inhibitors with Anticoagulants in Chronic Myeloid Leukemia : A Systematic Review (ASH 2024) - "Of the 3 retrospective studies, 2 reported no bleeding or thrombotic events with the combinations of ponatinib and prophylactic apixaban (5 patients) or imatinib with warfarin (9 patients) in CML patients. The third study reported the incidence of 2 intramuscular hematoma events with the combinations of edoxaban with imatinib (with severe renal failure leading to edoxaban discontinuation) and rivaroxaban with nilotinib (with moderate renal failure leading to rivaroxaban dose reduction).Five identified case reports (n(total cases)= 8) did not identify any bleeding events with the combinations of apixaban with dasatinib or imatinib (n= 2), warfarin with nilotinib or dasatinib (n= 1), therapeutic heparin with imatinib (n= 1), and imatinib with the combination of rivaroxaban with ticagrelor (n= 1). One study reported worsening of disseminated intravascular coagulation with the combination of imatinib and prophylactic danaparoid in a patient in blast phase of CML that..."

Clinical • Review • Atrial Fibrillation • Cardiovascular • Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Renal Disease • Thrombosis

LMWH-Associated Skin Necrosis in Heparin-Induced Thrombocytopenia Type II: A Case Requiring Complex Interdisciplinary Wound Management (EADV 2025) - "Materials & An 83-year-old woman was referred with necrotic plaques on both upper thighs and the lower left abdomen, localized to prior LMWH (enoxaparin) injection sites. This case reinforces the need to recognize skin necrosis as a manifestation of HIT II. In suspected cases, the 4Ts score should guide further testing. Immediate discontinuation of heparin, lifelong avoidance, and initiation of non-heparin anticoagulants such as danaparoid, argatroban or fondaparinux are essential to prevent thrombotic complications."

Clinical • Cardiovascular • Hematological Disorders • Immunology • Musculoskeletal Diseases • Orthopedics • Pulmonary Embolism • Respiratory Diseases • Thrombocytopenia

A singular case of refractory paraneoplastic heparin independent antiPF4-related thrombotic disorder (ISTH 2025) - "After prednisone withdrawal, in December 2024, Fostamatinib 200 mg daily was started...As hyperfibrinolysis signs appeared, a tranexamic acid course per os was also started. Results After starting pembrolizumab in November 2024, results on coagulopathy and platelet count were not appreciable. In December 2024, under Danaparoid and Fostamatinib (acetylsalicylic acid withdrawn after further platelet count fall in November 2024), he was admitted to Cardiology Unit (different hospital) after pulmonary embolism and myocardial infarction and died. At admission platelet count raise was finally appreciable, but coagulopathy was still present. Table or Figure Upload"

Clinical • Immune Thrombocytopenic Purpura • Immunology • Lung Cancer • Myocardial Infarction • Obesity • Oncology • Pulmonary Embolism • Respiratory Diseases • Solid Tumor • Thrombocytopenia • Thrombocytopenic Purpura • Thrombosis

Bleeding and Thrombosis Risks with Danaparoid Sodium in HIT: A Retrospective Study (ISTH 2025) - "Longer duration of danaparoid treatment, lower first anti-Xa level (0.3 U/mL IQR 0.3–0.5 vs 0.5 IQR 0.4–0.7) and high number of days with anti-Xa under the target (16 IQR 9–24 vs 1 IQR 0–6) were identified as risk factors for thrombosis. Indeed, the first anti-Xa was lower in the thrombosis group (median 0.3 UI/mL IQR 0.3–0.5) compared to the non-thrombosis group (0.5 UI/mL IQR 0.4–0.7, p=0.028)."

Retrospective data • Cardiovascular • Hematological Disorders • Thrombocytopenia • Thrombosis

"Keep HIT in Mind and Take Care". Multiple Tips From a Single Patient. (PubMed, Int Med Case Rep J) - "Discontinuation of warfarin could lead to catastrophic consequences if an unrecognized HIT is ongoing, and an alternative anticoagulant is not started. Bivalirudin and danaparoid were used after the diagnosis of HIT, adapting anticoagulant therapy to the needs of recent surgery."

Journal • Cardiovascular • Hematological Disorders • Thrombocytopenia • Thrombosis

Danaparoid failure in heparin-induced thrombocytopenia due to acquired antithrombin deficiency: A case report. (PubMed, Thromb Res) - "This is the first reported case of danaparoid failure due to a documented AT deficiency demonstrating the potential efficacy of AT supplementation in this context. This case highlights the importance of monitoring AT levels in HIT patients when danaparoid activity is below the therapeutic range despite adjusted dosing."

Journal • Cardiovascular • Hematological Disorders • Oncology • Sarcoma • Solid Tumor • Thrombocytopenia

Comparison of adverse drug reactions of heparin and its derivates in the European Economic Area based on data from EudraVigilance between 2017 and 2021. (PubMed, Clin Nephrol) - "The reporting rates of ADRs for heparin and its derivates were all very low. In comparison, the reporting rate of ADRs for danaparoid and fondaparinux was relatively high. The most commonly reported ADRs were hemorrhage, thrombocytopenia, followed by injection-site reactions and hypersensitivity."

Adverse drug reaction • Journal • Hematological Disorders • Hepatology • Immunology • Liver Failure • Orthopedics • Renal Disease • Thrombocytopenia

PROPHYLACTIC USE OF DANAPAROID AFTER LIVER TRANSPLANT IN HEPARIN-INDUCED THROMBOCYTOPENIA (HIT): A CASE REPORT (SIE 2024) - "A switch from LMWH to fondaparinux (FO) (2.5 mg daily) was opted for...At 1-month follow-up, the DVT had resolved, but given the need for ACT to maintain flow in the TIPS in view of liver transplantation (LT), a switch to a treatment with DAPT + Warfarin and then only with Clopidogrel...Prophylaxis was continued for another two months with FO (2.5 mg daily) and, at the end of two months, acetylsalicylic acid (75 mg daily) was started...Conclusions. We report the first case of successful and prolonged use of DA at prophylactic dose in prevention of thrombotic complications after LT in a patient with previous diagnosis of HIT."

Case report • Clinical • Cardiovascular • Cerebral Hemorrhage • Fibrosis • Hematological Disorders • Hepatology • Hypertension • Immunology • Liver Cirrhosis • Myocardial Infarction • Thrombocytopenia • Thrombosis • Transplantation

Antithrombotic Efficacy and Bleeding Risks of Vaccine-Induced Immune Thrombotic Thrombocytopenia Treatments. (PubMed, Blood Adv) - "Here, we examined the effects of various anticoagulants (including unfractionated (UF) heparin, danaparoid, bivalirudin, fondaparinux, and argatroban), IVIg, and the FcγRIIa receptor-blocking antibody, IV.3. Our results underscore the necessity of animal model investigations to inform and better guide clinicians on treatment choices. This study provides compelling evidence for developing FcγRIIa receptor blockers to prevent thrombosis in VITT and other FcγRIIa-related inflammatory disorders."

Journal • Cardiovascular • Hematological Disorders • Inflammation • Thrombocytopenia • Thrombosis

Management of Heparin-Induced Thrombocytopenia: A Contemporary Review. (PubMed, J Clin Med) - "In comparison to parenteral options (e.g., bivalirudin and danaparoid), they are easier to administer, are more cost-effective, and obviate the need for transition to an oral anticoagulant after platelet recovery. We also identify the knowledge gaps and suggest areas for future research."

Journal • Review • Cardiovascular • Hematological Disorders • Thrombocytopenia • Thrombosis • Venous Thromboembolism

PLATELET INDEX CHANGES INDUCED BY CIRCULATING HISTONES: COMPARISON BETWEEN HEPARINS AS THERAPEUTIC APPROACH (ISLH 2024) - "Here we described the ability of two glycosaminoglycan-based heparins (Danaparoid and Fondaparinux) to counteract the effects of circulating free histones on platelets. Circulating free histones are critically involved in inflammatory monocyte activation and in concomitant significant thrombocytopenia (due to consumption/aggregation of platelets), as found in many diseases and viral/bacterial sepsis. The low molecular weight heparinoid Danaparoid revealed a potent activity as histone-neutralizing agent, mainly based on their charge interactions, opening future perspective for therapeutic options."

Cardiovascular • Hematological Disorders • Infectious Disease • Inflammation • Septic Shock • Thrombocytopenia • Thrombosis

UniXa: Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels (clinicaltrials.gov) - P=N/A | N=2100 | Recruiting | Sponsor: Nantes University Hospital | Not yet recruiting ➔ Recruiting | Trial completion date: Jan 2023 ➔ May 2024 | Trial primary completion date: Jan 2023 ➔ May 2024

Enrollment open • Trial completion date • Trial primary completion date • Atrial Fibrillation • Cardiovascular • Venous Thromboembolism

AN UNUSUAL PRESENTATION OF HEPARIN INDUCED THROMBOCYTOPENIA (ACC 2024) - "While not a routine part of the workup for HIT, cardiac imaging can play a role in the detection of thrombus before a systemic embolic event, as in this case. High-risk populations, such as patients undergoing cardiac surgery, have up to a 5-fold risk of developing heparin-induced platelet antibodies and the clinical HIT syndrome. All heparin products should be immediately discontinued in patients with suspected or confirmed HIT."

Cardiovascular • Hematological Disorders • Thrombocytopenia • Thrombosis